Edition:
United Kingdom

AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

4,881.00GBp
15 Dec 2017
Change (% chg)

-3.50 (-0.07%)
Prev Close
4,884.50
Open
4,889.00
Day's High
4,889.00
Day's Low
4,846.50
Volume
3,606,336
Avg. Vol
2,466,307
52-wk High
5,585.07
52-wk Low
4,136.50

Select another date:

Mon, Dec 4 2017

BRIEF-Astrazeneca Says Phase IV Ascent Trial Meets Primary Endpoints

* PHASE IV ASCENT TRIAL MEETS PRIMARY ENDPOINTS IN COPD PATIENTS WITH CARDIOVASCULAR RISK FACTORS‍​ Source text for Eikon: Further company coverage:

BRIEF-G1 Therapeutics And AstraZeneca Enter Clinical Trial Collaboration In Non-Small Cell Lung Cancer

* G1 THERAPEUTICS AND ASTRAZENECA ENTER CLINICAL TRIAL COLLABORATION IN NON-SMALL CELL LUNG CANCER

BRIEF-Astrazeneca Plc says EMA accepts Tagrisso submission for 1st-line nsclc

* ‍EUROPEAN MEDICINES AGENCY ACCEPTS REGULATORY SUBMISSION FOR TAGRISSO IN 1ST-LINE EGFR-MUTATED NON-SMALL CELL LUNG CANCER​ Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

AstraZeneca steps up China push with new drug joint venture

LONDON Drugmaker AstraZeneca plans to turbo-charge its already substantial Chinese business through a new drug development joint venture with a state-backed private equity fund.

BRIEF-Astrazeneca makes regulatory submission for tagrisso in 1st-line egfr-mutated non-small cell lung cancer in Japan​

* ‍ASTRAZENECA MAKES REGULATORY SUBMISSION FOR TAGRISSO IN 1ST-LINE EGFR-MUTATED NON-SMALL CELL LUNG CANCER IN JAPAN​ Source text for Eikon: Further company coverage: (bangalore.newsroom@thomsonreuters.com)

AstraZeneca steps up China push with new drug joint venture

LONDON Drugmaker AstraZeneca plans to turbo-charge its already substantial Chinese business through a new drug development joint venture with a state-backed private equity fund.

AstraZeneca steps up China push with new drug joint venture

LONDON, Nov 27 Drugmaker AstraZeneca plans to turbo-charge its already substantial Chinese business through a new drug development joint venture with a state-backed private equity fund.

BRIEF-Almirall announces achievement of $80 mln sales-related milestones from agreement with Astrazeneca‍​

* ANNOUNCES ACHIEVEMENT OF $80 MILLION SALES-RELATED MILESTONES FROM AGREEMENT WITH ASTRAZENECA‍​ Source text for Eikon:

AstraZeneca ticks another box as U.S. approves severe asthma drug

(This version of the Nov.15 story corrects the spelling of the drug in paragraphs 8, 9)

REFILE-UPDATE 1-AstraZeneca ticks another box as U.S. approves severe asthma drug

LONDON, Nov 15 AstraZeneca has achieved another milestone in rebuilding its drug portfolio with U.S. approval of a drug for severe asthma as the company battles to put patent losses on older medicines behind it.

Select another date: